Tuesday, 26 November 2024
  
Login

Australia's most trusted
source of pharma news

Tuesday, 26 November 2024
News

The newest buster on the block

Posted 22 November 2024 AM

Bayer's Nubeqa has officially hit blockbuster status, largely compensating for the drop in revenue from Xarelto in the third quarter of this year.

In the first nine months of 2024, global sales of Bayer's androgen receptor inhibitor used to treat prostate cancer earned 1,080 million euros in revenue. That equates to US$1.14 billion, confirming that Nubeqa has hit blockbuster status. Last year it came close, earning 869 million euros (US$916.7 million) for the full year.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.